Targets › ERBB4
32 programs from 29 companies in 39 trials: 24 Phase 2, 11 Phase 1, 3 Phase 3, 1 Phase 4; Oncology; next expected readout Dec 2026.
Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. (UniProt, Q15303)
Open in Phaseline: the race on ERBB4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Michael Hopp | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 4 | Non-squamous NSCLC | Dec 2026 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Early-stage Breast Cancer | Feb 2028 |
| Region Skane | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| Region Skane | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 3 | Non-Small Cell Lung Cancer | Sep 2028 |
| National University Hospital, Singapore | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC | Dec 2026 |
| Yale University | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | HER2/Neu+ Uterine Serous Carcinoma | Dec 2026 |
| Ruth O'Regan | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Dec 2026 |
| National Cancer Institute (NCI) | Afatinib Dimaleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Lymphoma | Jan 2027 |
| H. Lee Moffitt Cancer Center and Research Institute | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Squamous Cell Carcinoma | Feb 2027 |
| National Cancer Institute (NCI) | Neratinib Maleate Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Malignant Female Reproductive System Neoplasm; Metastatic Malignant Solid Neoplasm | Feb 2027 |
| National Cancer Centre, Singapore | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IIIB; Advanced Solid Tumours | Apr 2027 |
| Shanghai Chest Hospital | Dacomitinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Non-small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer (NSCLC) | May 2027 |
| University Health Network, Toronto | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Jul 2027 |
| University of Texas Southwestern Medical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Squamous Non Small Cell Lung Cancer | Sep 2027 |
| University of Rochester | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer | Sep 2027 |
| National Taiwan University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | NSCLC Stage IV | Oct 2027 |
| Massachusetts General Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Lung Cancer; Advanced Solid Tumor | Dec 2027 |
| Shandong Public Health Clinical Center | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Carcinoma, Non-Small-Cell Lung | Dec 2027 |
| David Reardon, MD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Glioblastoma | Feb 2028 |
| H. Lee Moffitt Cancer Center and Research Institute | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | GastroEsophageal Cancer | Mar 2028 |
| Fudan University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Breast Cancer With Brain Metastasis | Aug 2029 |
| Scott R. Plotkin, MD, PhD | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Neurofibromatosis Type 2 | Dec 2029 |
| Spanish Breast Cancer Research Group | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Early-stage Breast Cancer | Jan 2030 |
| Vanderbilt-Ingram Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Anatomic Stage I Breast Cancer | Apr 2030 |
| Dartmouth-Hitchcock Medical Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 2 | Advanced Breast Cancer | Oct 2030 |
| Jeeyun Lee | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Stomach Neoplasm | Dec 2026 |
| West China Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | HNSCC; Esophagus Cancer | May 2027 |
| Fox Chase Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Gastric Cancer | Jun 2027 |
| Memorial Sloan Kettering Cancer Center | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Solid Tumor | Oct 2027 |
| Virginia Commonwealth University | Neratinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Advanced Solid Tumor | Oct 2027 |
| Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Fanconi Anemia | Dec 2028 |
| China Medical University Hospital | Afatinib Epidermal growth factor receptor erbB1 inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor; Receptor protein-tyrosine kinase erbB-4 inhibitor | EGFR, ERBB2, ERBB4 | Phase 1 | Non-small Cell Lung Cancer | – |
Breast Cancer (3) Advanced Lymphoma (3) Advanced Solid Tumor (2) Non-Small Cell Lung Cancer (2) Early-stage Breast Cancer (2) Non-squamous NSCLC (1) Non-small Cell Lung Cancer (1) NSCLC Stage IV (1) Squamous Cell Carcinoma (1) Lung Cancer (1) Solid Tumor (1) GastroEsophageal Cancer (1)
small molecule (23), mixed (7), antibody (1)
H. Lee Moffitt Cancer Center and Research Institute (2) Region Skane (2) National Cancer Institute (NCI) (2) Michael Hopp (1) China Medical University Hospital (1) National Taiwan University Hospital (1) Massachusetts General Hospital (1) University Health Network, Toronto (1) Memorial Sloan Kettering Cancer Center (1) Fox Chase Cancer Center (1) Shanghai Chest Hospital (1) Scott R. Plotkin, MD, PhD (1) Jeeyun Lee (1) National University Hospital, Singapore (1) Fudan University (1) Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) University of Rochester (1) Dartmouth-Hitchcock Medical Center (1) Spanish Breast Cancer Research Group (1) National Cancer Centre, Singapore (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.